AcquisitionsJun 22, 2026, 07:02 AM
Galmed Acquires Colospan for $3.3M Cash + $2M Earnout
AI Summary
Galmed Pharmaceuticals Ltd. announced the consummation of its acquisition of Colospan Ltd. on June 22, 2026. The deal involves a $3.3 million cash payment and a performance-based earnout of up to $2.0 million, with restructured terms to minimize immediate shareholder dilution. Colospan's CG-100, a CE-marked medical device for colorectal surgery, provides Galmed with a commercially ready product in the EU/Israel, aligning with Galmed's strategic focus on the GI space and aiming to generate top-line revenue faster.
Key Highlights
- Galmed Pharmaceuticals Ltd. consummated the acquisition of Colospan Ltd. on June 22, 2026.
- Total consideration includes $3.3 million in cash and up to $2.0 million in performance-based earnout.
- Earnout payments begin July 1, 2027, at 7% for sales $5M-$12M and 9% for sales over $12M.
- Colospan's CG-100 medical device is CE-marked in EU/Israel with a dedicated OPS code in Germany.
- CG-100 clinical trials showed 90% of patients avoided stoma creation and 0% mortality.
- Restructured terms included an additional $800K cash payment to reduce shareholder dilution.
- Galmed's cash balance was $15.6 million as of March 31, 2026.
- Preliminary purchase price allocation includes $4.9 million for goodwill and intangible assets.
Price Impact
More from GLMD